| rifampicin | Oral Liquid | 20 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 19/12/2025 |
| salbutamol sulfate | Inhalation, conventional | 3 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| salbutamol sulfate | Inhalation, conventional | 6 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| topiramate | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 19/12/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| lamotrigine | Tablet, chewable | 200 mg | Resolved | Available | Manufacturing | 19/12/2025 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Resolved | Available | Manufacturing | 19/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| exemestane | Tablet, sugar coated | 25 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| quetiapine fumarate | Tablet, modified release | 230.26 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| clindamycin hydrochloride | Capsule, hard | 162.87 mg | Resolved | Available | Manufacturing | 19/12/2025 |
| levetiracetam | Injection, intravenous infusion | 100 mg/mL | Anticipated | Available | Manufacturing | 19/12/2025 |
| phenylephrine hydrochloride~prednisolone acetate | Eye Drops, suspension | 1.2 mg/mL~10 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 19/12/2025 |
| isotretinoin | Capsule, soft | 20 mg | Anticipated | Available | Manufacturing | 19/12/2025 |
| irbesartan | Tablet, film coated | 75 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 20 mg~12.5 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| acamprosate calcium | Tablet, enteric coated | 333 mg | Resolved | Available | Manufacturing | 19/12/2025 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 19/12/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| lorazepam | Tablet | 1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 19/12/2025 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| levothyroxine sodium | Tablet, uncoated | 200 microgram | Current | Unavailable | Manufacturing | 19/12/2025 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Current | Unavailable | Manufacturing | 19/12/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Current | Limited Availability | Manufacturing | 19/12/2025 |
| anastrozole | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 19/12/2025 |
| hydralazine hydrochloride | Injection, powder for | 20 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| isotretinoin | Capsule, soft | 20 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 19/12/2025 |
| teicoplanin~water for injections | Diluent, not applicable~Injection, powder for | 400 mg~3.14 mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/12/2025 |
| alfuzosin hydrochloride | Tablet, modified release | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/12/2025 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Current | Unavailable | Manufacturing | 18/12/2025 |
| doxorubicin hydrochloride | Injection | 2 mg/mL | Anticipated | Available | Manufacturing | 18/12/2025 |
| atomoxetine hydrochloride | Capsule, hard | 11.43 mg | Current | Unavailable | Manufacturing | 18/12/2025 |
| cyproterone acetate | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 18/12/2025 |
| ambrisentan | Tablet, film coated | 5 mg | Anticipated | Available | Manufacturing | 18/12/2025 |
| dantrolene sodium hemiheptahydrate | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 17/12/2025 |
| glipizide | Tablet, uncoated | 5 mg | Resolved | Available | Manufacturing | 17/12/2025 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 17/12/2025 |
| plerixafor | Injection, solution | 20 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 17/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 17/12/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Current | Unavailable | Manufacturing | 17/12/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 17/12/2025 |
| armodafinil | Tablet, uncoated | 250 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 17/12/2025 |
| armodafinil | Tablet, uncoated | 150 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 17/12/2025 |
| cisatracurium besilate | Injection, solution | 7.04 mg | Current | Limited Availability | Manufacturing | 17/12/2025 |
| metformin hydrochloride | Tablet, modified release | 500 mg | Current | Unavailable | Manufacturing | 17/12/2025 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Current | Unavailable | Manufacturing | 17/12/2025 |
| levothyroxine sodium | Tablet | .075 mg | Anticipated | Available | Manufacturing | 17/12/2025 |
| ramipril | Tablet, uncoated | 1.25 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 17/12/2025 |
| Teriparatide | Injection, solution | 250 microgram/mL | Current | Unavailable | Manufacturing | 17/12/2025 |
| metronidazole | Tablet, film coated | 400 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 17/12/2025 |
| stannous chloride dihydrate | Injection, powder for | 19.2 microgram/mL | Current | Emergency Supply Only | Manufacturing | 17/12/2025 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Anticipated | Available | Manufacturing | 17/12/2025 |
| labetalol hydrochloride | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 17/12/2025 |
| olanzapine | Tablet, film coated | 5 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/12/2025 |
| midazolam | Injection, solution | 1 mg/mL | Resolved | Available | Manufacturing | 17/12/2025 |
| hydrochlorothiazide~enalapril maleate | Tablet, uncoated | 6 mg~20 mg | Resolved | Available | Manufacturing | 17/12/2025 |
| olanzapine | Wafer | 5 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 17/12/2025 |
| cefalexin monohydrate | Capsule, hard | 263 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 17/12/2025 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 17/12/2025 |
| etoposide phosphate | Injection, powder for | 1136 mg | Anticipated | Available | Manufacturing | 17/12/2025 |
| gabapentin | Capsule, hard | 400 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Current | Unavailable | Unexpected increase in consumer demand | 16/12/2025 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Anticipated | Available | Unexpected increase in consumer demand | 16/12/2025 |
| valaciclovir | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Current | Limited Availability | Manufacturing | 16/12/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 16/12/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.768 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 16/12/2025 |
| leflunomide | Tablet, film coated | 20 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| Somatropin | Injection, powder for | 12 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 16/12/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Current | Unavailable | Manufacturing | 16/12/2025 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 160 mg~12.5 mg | Anticipated | Available | Manufacturing | 16/12/2025 |
| oseltamivir phosphate | Oral Liquid, powder for | 7.88 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 16/12/2025 |
| levodopa~carbidopa monohydrate~entacapone | Tablet, film coated | 200 mg~54 mg~200 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| levodopa~carbidopa monohydrate~entacapone | Tablet, film coated | 75 mg~20.25 mg~200 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 13.5 mg~200 mg~50 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| levodopa~entacapone~carbidopa monohydrate | Tablet, film coated | 100 mg~200 mg~27 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| entacapone~levodopa~carbidopa monohydrate | Tablet, film coated | 200 mg~125 mg~33.75 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| entacapone~carbidopa monohydrate~levodopa | Tablet, film coated | 200 mg~40.5 mg~150 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| quetiapine fumarate | Tablet, modified release | 57.5 mg | Current | Limited Availability | Unexpected increase in consumer demand | 16/12/2025 |
| stiripentol | Capsule | 500 mg | Anticipated | Available | Manufacturing | 16/12/2025 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Current | Unavailable | Manufacturing | 16/12/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Unavailable | Unexpected increase in consumer demand | 16/12/2025 |
| sacubitril~valsartan | Tablet, film coated | 97.2 mg~102.8 mg | Current | Unavailable | Manufacturing | 16/12/2025 |
| rivaroxaban | Tablet, film coated | 15 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 16/12/2025 |
| aripiprazole monohydrate | Injection, powder for | 416.07 mg | Current | Unavailable | Manufacturing | 16/12/2025 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Resolved | Available | Manufacturing | 16/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | 1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .125 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/12/2025 |
| diltiazem hydrochloride | Capsule, modified release | 180 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| diltiazem hydrochloride | Capsule, modified release | 360 mg | Current | Unavailable | Manufacturing | 16/12/2025 |
| diltiazem hydrochloride | Capsule, modified release | 360 mg | Anticipated | Available | Manufacturing | 16/12/2025 |
| flunitrazepam | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Resolved | Available | Manufacturing | 16/12/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Unavailable | Manufacturing | 16/12/2025 |
| simvastatin | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 16/12/2025 |
| Pancreatic extract | Capsule, enteric | 300 mg | Current | Limited Availability | Unexpected increase in consumer demand | 15/12/2025 |
| lansoprazole | Capsule, enteric | 30 mg | Resolved | Available | Manufacturing | 15/12/2025 |
| avanafil | Tablet, uncoated | 200 mg | Anticipated | Available | Unexpected increase in consumer demand | 15/12/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 15/12/2025 |
| lacosamide | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 15/12/2025 |
| lacosamide | Tablet, film coated | 150 mg | Resolved | Available | Manufacturing | 15/12/2025 |
| Pancreatic extract | Capsule | 420 mg | Current | Limited Availability | Unexpected increase in consumer demand | 15/12/2025 |
| estradiol | Drug delivery system, transdermal | 1.17 mg | Current | Unavailable | Manufacturing | 15/12/2025 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Manufacturing | 15/12/2025 |
| lanreotide acetate | Injection, solution | 100 mg | Current | Unavailable | Manufacturing | 15/12/2025 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 15/12/2025 |
2025年12月22日